Review Details Interleukin-1's Central Role in Osteoarthritis Pathophysiology and Targeted Therapeutic Strategies

Osteoarthritis (OA) is a highly prevalent degenerative joint disease causing chronic pain and disability, characterized by progressive articular cartilage degeneration, synovial inflammation, and aberrant subchondral bone remodeling. Current treatments often fall short in modifying disease progression, primarily addressing symptoms. Chronic, low-grade inflammation is a critical driver of OA, disrupting joint tissue homeostasis. Interleukin-1 (IL-1), particularly IL-1β, is a pivotal pro-inflammatory cytokine recognized for its potent catabolic effects on cartilage, making its signaling pathway a promising, yet clinically challenging, therapeutic target.

This comprehensive review systematically analyzed the current literature on Interleukin-1 (IL-1) and its regulatory mechanisms within the context of Osteoarthritis (OA) pathophysiology. The authors detailed IL-1's central role in driving cartilage degradation and inflammation, specifically dissecting its key downstream signaling pathways, including NF-κB and MAPK activation. Furthermore, the review provided a critical appraisal of both current and emerging therapeutic strategies that specifically target the IL-1 pathway, evaluating their potential to modify disease progression and alleviate symptoms based on existing evidence.

The review highlighted IL-1, especially IL-1β, as a central mediator in OA pathogenesis, exerting significant catabolic effects on joint tissues. It promotes the expression of matrix-degrading enzymes like MMPs and ADAMTS while simultaneously suppressing the synthesis of essential extracellular matrix components such as type II collagen and aggrecan, thereby accelerating cartilage breakdown and hindering repair. Key downstream signaling pathways activated by IL-1, including NF-κB and MAPK, were identified as crucial for mediating these destructive processes. The review synthesized the landscape of IL-1-targeted therapeutic strategies, noting their potential to modify disease progression. However, it also underscored the clinical limitations and challenges associated with these approaches, suggesting that while promising, their full therapeutic potential in OA has yet to be realized. > IL-1 signaling is a pivotal, yet clinically limited, therapeutic target due to its dual action of promoting cartilage degradation and suppressing repair via pathways like NF-κB and MAPK.